Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
ISRCTN |
Last refreshed on:
|
17 October 2016 |
Main ID: |
ISRCTN20012465 |
Date of registration:
|
15/12/2015 |
Prospective Registration:
|
No |
Primary sponsor: |
|
Public title:
|
Pharmacokinetics study of a single bolus intravenous injection of diclofenac sodium solution administered in male and female healthy volunteers
|
Scientific title:
|
Pharmacokinetics study of a single bolus intravenous injection of diclofenac sodium solution administered in male and female healthy volunteers: single dose, open-label, four-part pharmacokinetic study. |
Date of first enrolment:
|
13/04/2015 |
Target sample size:
|
53 |
Recruitment status: |
Completed |
URL:
|
http://isrctn.com/ISRCTN20012465 |
Study type:
|
Interventional |
Study design:
|
Single dose open-label randomised cross-over four-part pharmacokinetics study. (Other)
|
Phase:
|
Phase I
|
|
Countries of recruitment
|
Switzerland
| | | | | | | |
Contacts
|
Name:
|
Milko
Radicioni |
Address:
|
CROSS Research Phase I Unit
Via F. A. Giorgioli 14
CH-6864
Arzo
Switzerland |
Telephone:
|
|
Email:
|
|
Affiliation:
|
|
|
Name:
|
|
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
|
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: 1. Informed consent 2. Females and males, 18-55 years old inclusive 3. Body Mass Index (BMI): 18.5-30 kg/m2 inclusive 4. Vital signs: systolic blood pressure 100-139 mmHg, diastolic blood pressure 50-89 mmHg, heart rate 50-90 bpm 5. Females of child-bearing potential using reliable methods of contraception 6. Females of non-child-bearing potential or in post-menopausal status for at least 1 year 7. For all female subjects, pregnancy test result must be negative at screening
Exclusion criteria: 1. ECG 12-leads (supine position): clinically relevant abnormalities 2. Clinically relevant abnormal physical findings 3. Clinically relevant abnormal laboratory values 4. Ascertained or presumptive hypersensitivity to the active principle and/or formulations' ingredients or other non-steroidal anti-inflammatory drugs (NSAIDs); history of anaphylaxis to drugs or allergic reactions in general, which the investigator considers may affect the outcome of the study. History of asthma 5. Relevant history of significant renal, hepatic, gastrointestinal (in particular active or suspected gastrointestinal ulcers or bleeding), genitourinary, cardiovascular, respiratory, skin, haematological, endocrine or neurological diseases that may interfere with the aim of the study. History of haemorrhagic diathesis, thalassemia, sickle-cell disease, G6PD deficiency and any other condition that could potentially lead to haemolysis 6. Intake of medications, including over-the-counter (OTC) medications and herbal products for 2 weeks before the start of the study. In particular NSAID or anticoagulant use for 2 weeks before and during the entire study. Hormonal contraceptives for females are allowed 7. Participation in the evaluation of any investigational product in the 3 months before this study 8. Blood donations in the 3 months before this study 9. History of drug, alcohol [> 1 drink/day for females and >2 drinks/day for males, defined according to USDA Dietary Guidelines 2010 (8)], caffeine (>5 cups coffee/tea/day) or tobacco abuse (=10 cigarettes/day) 10. Positive result at the drug test at screening 11. Positive alcohol breath test 12. Abnormal diets (<1600 or >3500 kcal/day) or substantial changes in eating habits in the 4 weeks before this study; vegetarians 13. Positive or missing pregnancy test at screening or day -1, pregnant or lactating women
Age minimum:
Age maximum:
Gender:
Both
|
Health Condition(s) or Problem(s) studied
|
Exposure (AUC) of diclofenac sodium in healthy adults Not Applicable
|
Intervention(s)
|
Part 0: Each volunteer was assigned to a cohort according to a dose-escalation design (3 subjects to treatment T1, 3 subjects to treatment T2 and 3 subjects to treatment T3) and received one single dose of one of the following test treatments in 1 period per cohort, for a minimum study duration of 11 days, screening visit included: 1. Test treatment T1: Akis, diclofenac sodium 25 mg/1 mL solution for injection in prefilled syringe, IBSA Farmaceutici Italia S.r.l., Italy - injection rate 5 sec 2. Test treatment T2: Akis, diclofenac sodium 50 mg/1 mL solution for injection in prefilled syringe, IBSA Farmaceutici Italia S.r.l., Italy - injection rate 5 sec 3. Test treatment T3: Akis, diclofenac sodium 75 mg/1 mL solution for injection in prefilled syringe, IBSA Farmaceutici Italia S.r.l., Italy - injection rate 5 sec
Part 1: Each volunteer was randomised to receive the following four study treatments in the 4 study periods, according to a computer generated randomisation list, separated by a wash-out interval of at least 7 days, for a minimum study duration of 34 days, screening visit included: 1. Test treatment T3: Akis, diclofenac sodium 75 mg/1 mL solution for injection in prefilled syringe, IBSA Farmaceutici Italia S.r.l., Italy - injection rate 5 sec 2. Test treatment T4: Akis, diclofenac sodium 75 mg/1 mL solution for injection in prefilled syringe, IBSA Farmaceutici Italia S.r.l., Italy - injection rate 15 sec 3. Test treatment T5: Akis, diclofenac sodium 75 mg/1 mL solution for injection in prefilled syringe, IBSA Farmaceutici Italia S.r.l., Italy - injection rate 30 sec 4. Reference formulation R: VOLTAREN, diclofenac sodium 75 mg/3 mL solution for intramuscular injection in ampoules, Novartis Farma S.p.A., Italy
Part 2: Each volunteer was randomised to receive the following four study treatments in the 3 study periods, according to a computer generated randomisation list, separated by a wash-out interval of at least 7 days, for a minimum study duration of 2
|
Primary Outcome(s)
|
Part 0 (dose-escalation): to collect safety and tolerability data of T1, T2 and T3; to confirm the safety and tolerability of T3. Part 1 (rate of administration): to evaluate the PK profile of T3, T4 and T5 and determine the injection rate to be used in study Part 2 and 3 based on PK results and AEs occurrence; to evaluate the PK profile of R. Part 2 (comparative bioavailability): Primary end-point: to compare the bioavailability of Akis diclofenac sodium 75mg/1 mL administered as a single i.v. bolus injection at the rate selected in Part 1, of the R2 and of the R3, in terms of extent of exposure. Part 3 (descriptive pharmacokinetics): to further evaluate the PK profile of Akis 75mg/1 mL administered as a single i.v. bolus injection at the rate selected in Part 1.
Part 0: 1. Treatment emergent adverse events (TEAEs); 2. Thrombophlebitis assessment at the i.v. injection site, using a 6-point scale; 3. ECG, vital signs, body weight, laboratory parameters (haematology, biochemistry, immunohaematology).
Part 1: 1. Diclofenamic acid plasma Cmax, Tmax, AUC0-t, AUC0-8, MRT, Vz and t1/2 for T3, T4, T5 and R, C0 only for T3, T4 and T5; 2. Treatment emergent adverse events (TEAEs); 3. Thrombophlebitis assessment at the i.v. injection site, using a 6-point scale; 4. ECG, vital signs, body weight, laboratory parameters (haematology, biochemistry, immunohaematology).
Part 2: 1. Diclofenamic acid plasma AUC0-t and AUC0-8 (if feasible) for T3 or T4 or T5, as selected in Part 1, and for R2 and R3; 2. Treatment emergent adverse events (TEAEs); 3. Thrombophlebitis assessment at the i.v. injection site, using a 6-point scale; 4. ECG, vital signs, body weight, laboratory parameters (haematology, biochemistry, immunohaematology).
Part 3 (if needed): 1. Diclofenamic acid plasma C0, Cmax, Tmax, MRT, Vz and t1/2 for T3 or T4 or T5, as selected in Part 1.
In each period of study parts 1, 2 and 3, venous blood samples (8 mL) were collected at the following times: pre-dose (0), 3, 6, 10, 20, 30, 40, 50 min, 1, 1.25, 1.5, 2, 3, 4, 6 and 8 h post-dose.
|
Secondary ID(s)
|
Study CRO-PK-14-290 - Sponsor code 14CH-DCiv11
|
Source(s) of Monetary Support
|
IBSA Biochemical Institute SA
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|